You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Epidermal growth factor receptor mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 24, 2023

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    Learn About Dacomitnib in Non-small Cell Lung Cancer Which Has

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Oct 4, 2023

    Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

    Recruiting
    • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 21, 2023

    NSCLC Trial in Changsha (Furmonertinib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer hospital
    May 19, 2022

    Observational Study of Afatinib 30 mg Daily

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Epidermal Growth Factor Receptor Mutation
    • Singapore, Singapore
      Nationa University Hospital
    Apr 4, 2022

    OPTImal PALliative Anti-epidermal Growth Factor Receptor

    Active, not recruiting
    • Colorectal Cancer Metastatic
    • +5 more
    • Plasma circulating DNA analysis
    • Aarhus, Denmark
      Aarhus University Hospital
    Feb 24, 2022

    Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

    Recruiting
    • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 25, 2023

    NSCLC, EGF-R Positive NSCLC Trial in Shanghai (Furmonertinib)

    Recruiting
    • NSCLC
    • EGF-R Positive Non-Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai General Hospital
    Jan 12, 2022

    NSCLC Trial in Beijing (Icotinib, Cisplatin, Carboplatin)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Beijing, China
      BeijingCancerH
    Nov 2, 2021

    EGFR Mutation-Related Tumors Trial (NX-019)

    Not yet recruiting
    • EGFR Mutation-Related Tumors
    • (no location specified)
    Aug 22, 2022

    Real-world Data of Afatinib Treatment in First-line Setting and

    Active, not recruiting
    • Non-squamous, Non-Small Cell Lung Cancer
    • Tokyo, Japan
      Nippon Boehringer Ingelheim Co., Ltd.
    Jan 9, 2023

    Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

    Active, not recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +5 more
    • Laboratory Biomarker Analysis
    • +3 more
    • New Haven, Connecticut
    • +4 more
    Jan 27, 2023

    Observes Afatinib as First-line Treatment and Sequential Therapy

    Active, not recruiting
    • Non-squamous, Non-Small Cell Lung Cancer
    • Beijing, China
    • +9 more
    Jan 9, 2023

    PFS Trial in Qingdao (afatinib)

    Recruiting
    • PFS
    • Qingdao, Shandong, China
    • +1 more
    Feb 23, 2022

    NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)

    Recruiting
    • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    • Combined therapy of anlotinib and aumolertinib
    • Kunming, Yunnan, China
      First Affiliated Hospital of Kunming University
    Oct 22, 2023

    Lung Tumors, EGFR Gene Mutation Trial in Hwasun (Afatinib)

    Completed
    • Lung Neoplasms
    • EGFR Gene Mutation
    • Hwasun, Jeonnam, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Aug 1, 2021

    NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    • (no location specified)
    Aug 27, 2023

    NSCLC Without Mutation in Epidermal Growth Factor Receptor (Disorder) Trial (tereotactic body radiotherapy)

    Not yet recruiting
    • Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
    • tereotactic body radiotherapy
    • (no location specified)
    Dec 1, 2023

    EGFR Mutation Positive Non Small Cell Lung Cancer Trial in Sutton

    Active, not recruiting
    • EGFR Mutation Positive Non Small Cell Lung Cancer
      • Sutton, United Kingdom
        Royal Marsden
      Mar 5, 2021

      Non-small Cell Lung Carcinoma Trial (Drug: Furmonertinib 80 mg, Furmonertinib 80 mg )

      Not yet recruiting
      • Non-small Cell Lung Carcinoma
      • Drug: Furmonertinib 80 mg
      • Furmonertinib 80 mg placebo
      • (no location specified)
      Apr 19, 2021

      NSCLC Trial in Qingdao (osimertinib oral and bevazizumab intravenously)

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
      • osimertinib oral and bevazizumab intravenously
      • Qingdao, Shandong, China
        Qingdao Central Hospital, Qingdao Cancer Hospital
      Nov 1, 2021

      NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • (no location specified)
      May 23, 2023

      NSCLC Trial (Furmonertinib)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • (no location specified)
      Aug 10, 2023

      NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Telisotuzumab Vedotin
      • +4 more
      • (no location specified)
      Oct 17, 2023